60 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
Therapeutics, Inc merger agreement and severance and other related costs for former TCR2 Therapeutics leadership, offset by a decrease in share-based
8-K
EX-99.1
trh9zl1ncbyx7
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
3k2yz
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
xxzer68lpuqb4lv2 5n
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.4
k48713u x1
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
51qvjo
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
q9iyathi9jc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
1at2apyzri
22 May 23
Business combination disclosure
7:01am
8-K
3lohttifqidwpt9 pwl
22 May 23
Other Events
6:59am
424B3
pze2pe1t mdolgnp
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
b0zvqu8u99ks2 dpym
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
m0x8vjgsa
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-99.1
sb5vv7
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am